Antonio Gasbarrini

Antonio Gasbarrini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Antonio Gasbarrini has a total of 683 co-authors. Here are the top co-authors by number of shared publications:

  • Luca Miele

    CEMAD Digestive Diseases Center, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Rome, Italy

    9 shared publications
  • Maurizio Pompili

    Department of Medical and Surgical Sciences Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy

    8 shared publications
  • Maurizio Sanguinetti

    Dipartimento di Scienze biotecnologiche di base, cliniche intensivologiche e perioperatorie, Università Cattolica del Sacro Cuore, 00168 Rome, Italy

    7 shared publications
  • Francesca Romana Ponziani

    Liver Unit, CEMAD, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

    6 shared publications
  • Giovanni Addolorato

    Department of Medical and Surgical Sciences, CEMAD - Digestive System Disease Center, Internal Medicine and Gastroenterology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy; President, "Società Italiana di Alcologia" (SIA), Italy

    6 shared publications
  • Giovanni Cammarota

    6 shared publications

Latest Publications

  • Open Access

    Pancreatic fat and stiffness reflect distinct features of pancreatic remodeling and β-cell function

    by Sara Sofia De Lucia, Gea Ciccarelli, Giulia Gliozzo, Gianfranco Di Giuseppe, Laura Soldovieri, Emanuele Gentile, Enza Genco, Lorenzo Gallo, Maria Assunta Zocco, Maria Elena Ainora, et al.

    Context: Fatty pancreas is associated with obesity and metabolic alterations and may coexist with pancreatic structural remodeling. However, its contribution to β-cell dysfunction remains unclear. Objective: We investigated the relationship between pancreatic fat, tissue remodeling, and β-cell function. Design: We conducted a cross-sectional study in individuals with ultrasound-detected pancreatic hyperechogenicity without prior diagnosis of diabetes. Pancreatic fat was quantified by magnetic resonance imaging (MRI)-derived proton density fat fraction, while tissue stiffness was assessed by shear wave elastography. Metabolic phenotyping was based on oral glucose tolerance test (OGTT). Participants: We recruited 29 individuals with ultrasound-detected fatty pancreas (F/M 16/13, age 54 ± 10.4 years) and assessed glucose tolerance with OGTT: 75.9% exhibited normal glucose tolerance (n = 22), while 24.1% had impaired glucose tolerance (n = 7). Results: MRI-derived pancreatic fat fraction was positively correlated with anthropometric measures (body mass index ρ = 0.43, P = .02) and β-cell function (β-cell glucose sensitivity ρ = 0.40, P = .03). Pancreatic stiffness correlated negatively with body weight (ρ = −0.38, P = .04), did not correlate with pancreatic fat fraction (ρ = −0.15, P = .44), and was correlated inversely with the potentiation factor ratio 1 (ρ = −0.44, P = .02), a measure of non–glucose-dependent amplification of insulin secretion. Conclusion: Intrapancreatic fat and pancreatic stiffness appear to reflect distinct pathophysiological processes, with potentially different relationships to systemic metabolic status and β-cell function. These findings support a more nuanced view of pancreatic structural alterations as heterogeneous markers of metabolic dysfunction.


  • Perceived Satisfaction of Outpatients Undergoing Endoscopic Examination: A Cross-Sectional Observational Study

    by Fabio Grilli, Alessio Lo Cascio, Chiara Massari, Mattia Bozzetti, Michaela Angeletti, Veronica Brandinu, Eleonora Ribaudi, Maria Luigia Candela, Giovanni Cammarota, Alfredo Papa, et al.

    Introduction: Patient satisfaction is a key quality indicator in gastrointestinal endoscopy, influencing adherence, service improvement, and overall care experience. This study aimed to assess determinants of satisfaction among outpatients undergoing gastrointestinal endoscopic procedures. Methods: We conducted a cross-sectional study at the Digestive Endoscopy Service of a university hospital in Italy. Outpatients undergoing esophagogastroduodenoscopy, colonoscopy, or endoscopic ultrasound completed the Endoscopy Customer Satisfaction Questionnaire and the Perceived Stress Scale. Relevant sociodemographic and clinical data were collected. Statistical analyses included ANOVA, t-tests, Pearson’s correlation, and multiple linear regression. Results: A total of 203 outpatients were enrolled. Mean overall satisfaction score was 46.4 ± 9.2 (maximum score = 60). Higher satisfaction was associated with healthcare professionals’ competence, particularly nurses (p < 0.001), and with the interaction between nurse and endoscopist expertise. In multivariable analysis, gender, previous surgeries, bowel preparation timing, nurse competence, examination duration, and time spent in the endoscopy room were significant predictors of satisfaction, while perceived stress was not significantly associated with satisfaction. Conclusion: Nursing and medical expertise are crucial in shaping endoscopic patient satisfaction. Enhanced communication, reduced waiting times, and optimized procedural factors may improve patient experiences. Future research should explore strategies to increase satisfaction and adherence to follow-up procedures.

  • Open Access

    Timing of biologic prophylaxis and postoperative recurrence in Crohn’s disease: A real-life cohort study using propensity score weighting

    by Angelo Del Gaudio, Federica Di Vincenzo, Giuseppe Cuccia, Gaetano Coppola, Lucrezia Laterza, Franco Sacchetti, Paola Caprino, Luigi Sofo, Gabriele Dragoni, Elisa Foscarini, et al.

    Background: Postoperative recurrence is a major challenge in the management of Crohn’s disease after ileocolonic resection. Although international guidelines recommend early initiation of biologic prophylaxis, the optimal timing remains uncertain in real-world practice. Methods: We conducted a retrospective cohort study of Crohn’s disease patients undergoing ileocolonic resection. All patients received biologic prophylaxis within 16 weeks after surgery. Patients were stratified into 3 timing groups: 12 and ≤16 weeks. To account for baseline differences, a propensity score–based inverse probability of treatment weighting approach was applied. The primary outcome was endoscopic recurrence (ER) at 6 to 12 months. Results: Among 173 patients, 79 (46%) initiated biologic prophylaxis within 8 weeks after surgery, 32 (18%) between 8 and 12 weeks, and 62 (36%) between >12 and ≤16 weeks. ER at 6 to 12 months occurred in 103 (59.5%) patients. In the inverse probability of treatment weighting–weighted analysis, initiation of biologic therapy more than 12 weeks after surgery was associated with a significantly higher risk of ER compared with initiation within 8 weeks (risk ratio, 1.96; 95% confidence interval, 1.45-2.65; P < .001), whereas no significant difference was observed between initiation within 8 weeks and 8-12 weeks (risk ratio, 1.44; 95% confidence interval, 0.93-2.23; P = .10). In multivariable logistic regression analysis, smoking, prior intestinal resections, and delayed initiation of biologic prophylaxis were independently associated with ER. Conclusions: In half of patients, prophylactic biologic therapy was initiated more than 8 weeks after ileocolonic resection. Initiation of biologic prophylaxis beyond 12 weeks after surgery was associated with a significantly increased risk of ER.

  • Open Access

    Enhanced Liver Fibrosis Test, FIB ‐4 and FibroScan : Real‐World Prognostic Accuracy for MASLD in a Biopsy‐Controlled Cohort

    by Antonio Liguori, Francesca D'AMbrosio, Giulia Angelini, Consuelo Cefalo, Simone Galletti, Sara Cardinali, Maria Cristina Giustiniani, Giuseppe Marrone, Marco Biolato, Gianludovico Rapaccini, et al.

    Background and Aims: Liver fibrosis is a major determinant of liver‐related events (LREs) in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD). Effective stratification based on fibrosis severity is essential for accurate prognosis. The Enhanced Liver Fibrosis (ELF) test, a non‐invasive test measuring direct fibrosis markers, offers a potential alternative to traditional methods like FIB‐4, liver stiffness measurement (LSM) and liver biopsy. This study aims to evaluate the prognostic value of the ELF test in comparison with these established methods. Methods: We retrospectively analysed 289 MASLD patients (30.4% female, median age 49 years [IQR 39–58], 28% with type 2 diabetes) from the PROMETEO cohort (NCT04371042). We excluded patients with prior or current evidence of decompensated cirrhosis. At baseline, patients underwent liver biopsy, FIB‐4, ELF and LSM assessments. The primary outcome was development of Liver Related Events (LRE), a composite of liver‐related death, hepatocellular carcinoma, liver transplantation, ascites, encephalopathy or variceal bleeding. Results: Over a median follow‐up of 64 months [IQR 39–81], 41 patients (14.2%) experienced LREs. Event rates increased markedly across ELF categories (1% for ELF < 9.8, 27.8% for ELF ≥ 9.8 to < 11.3 and 72.7% for ELF ≥ 11.3). ELF demonstrated discriminative performance comparable to histological fibrosis stage and LSM, with the highest overall AUC among evaluated tests. In adjusted Cox models, higher ELF categories remained strongly associated with LRE risk, although confidence intervals were wide due to the limited number of events. Conclusions: In this biopsy‐proven MASLD cohort, ELF provided prognostic stratification for liver‐related events comparable to liver histology and LSM. Given the limited number of outcome events, these findings support the non‐inferiority of ELF rather than definitive superiority. Larger prospective studies are needed to confirm these results and refine risk prediction strategies.


  • Open Access

    Immunological and epithelial barrier dysfunction in EGPA: the possible role of new biomarkers

    by Cristiano Caruso, Ilaria Baglivo, Stefania Colantuono, Maria Antonietta Zavarella, David Longhino, Chiara Laface, Laura Bruno, Gabriele Lucca, Fabio Romano Selvi, Eleonora Di Carluccio, et al.

    Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic vasculitis with heterogeneous clinical manifestations. Identifying reliable biomarkers is crucial to predicting disease evolution and guiding therapy. We analyzed clinical, biological, and functional data from 33 patients with EGPA in the vasculitic phase. Blood eosinophil count (BEC), eosinophilic cationic protein (ECP), antineutrophil cytoplasmic antibodies (ANCAs), specific IgE to staphylococcal enterotoxins (SE-IgE), and serum free light chains (FLCs) were evaluated. Severe eosinophilic asthma (SEA) and chronic rhinosinusitis with nasal polyps (CRSwNPs) were present in 100% and 88.5% of patients, respectively. Median BEC was 1950 cells/mm3, with elevated ECP (60.0 µg/L). SE-IgE was detected in 54.2% of patients. A significant negative correlation emerged between λ FLCs and oral corticosteroid (OCS) dose (r = –0.58, p = 0.009). Forced expiratory volume in 1 second (FEV1) was significantly lower in C-ANCA+ patients (p = 0.006). ECP and SE-IgE may serve as markers of eosinophilic activity and epithelial barrier damage in EGPA. λ FLCs might be a useful indicator of OCS exposure and treatment response. These biomarkers could support the evaluation of disease evolution and treatment response.

  • Open Access

    MASLD Beyond the Liver: A Systemic Driver of Cardiovascular, Renal, and Oncologic Risk

    by Antonio Liguori, Valentin Calvez, Lucrezia Petrucci, Fabrizio Termite, Lidia Tomasello, Angela Sciarra, Simone Varca, Antonio Gasbarrini, Maurizio Pompili, Luca Miele

    Purpose of Review: This review aims to synthesize current evidence on metabolic dysfunction-associated steatotic liver disease (MASLD) as a systemic driver of extrahepatic complications beyond its hepatic manifestations. We sought to answer two key questions: (1) Which multisystemic diseases show independent associations with MASLD after adjustment for traditional cardiometabolic risk factors? (2) What shared pathophysiological mechanisms link hepatic steatosis to distant organ dysfunction? Recent Findings: Large cohort studies and meta-analyses demonstrate MASLD independently increases cardiovascular, renal, gastrointestinal, and oncologic risks, independently from traditional cardiometabolic risk factors. Key mechanisms include systemic inflammation, insulin resistance with hyperinsulinemia, endothelial dysfunction, visceral adipose tissue dysregulation, gut dysbiosis with metabolic endotoxemia, atherogenic dyslipidemia, PNPLA3 genetic variants, and oxidative stress. Hepatic fibrosis consistently amplifies multisystemic risk across organ systems. Summary: MASLD represents a multisystem metabolic disorder requiring integrated risk assessment. Systematic fibrosis staging emerges as the strongest disease-specific prognostic factor. Future research must develop risk prediction models and liver-directed interventions targeting the gut-liver axis to mitigate MASLD's growing population-level burden


  • Open Access

    Bone mineral density does not predict overall survival in patients with advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial.

    by Maximilian Thormann, Andreas Wienke, Ricarda Seidensticker, Kerstin Schütte, Christoph J. Zech, Christian Loewe, Otto van Delden, Vincent Vandecaveye, Chris Verslype, Bernhard Gebauer, et al.

    Background Low bone mineral density (BMD) is an increasingly recognized marker of skeletal frailty, associated with higher fracture risk and mortality in cancer patients. In advanced hepatocellular carcinoma (HCC), however, the prognostic significance of baseline BMD remains unclear. This exploratory subanalysis of the SORAMIC trial evaluated whether CT-derived BMD predicts overall survival (OS) in patients with unresectable HCC. Methods In this exploratory post-hoc study, 342 patients with unresectable HCC and preserved liver function (Child-Pugh ≤B7) were enrolled in the palliative arm of the SORAMIC trial and randomized to receive either sorafenib monotherapy (n=170) or selective internal radiation therapy (SIRT) plus sorafenib (n=172). BMD (in Hounsfield Units, HU) was measured at the third lumbar vertebra on pre-treatment contrast-enhanced CT scans. Patients were stratified into low and high BMD groups using three definitions: the cohort median (139.5 HU for men, 130.0 HU for women), <160 HU for men and <175 HU for women (Meister criteria), and <160 HU (Jang criteria). Cox regression analyses assessed the impact of BMD on OS. Results Median OS in the overall cohort was 9.9 months. No significant association between BMD and OS was observed in the entire cohort or within the sorafenib and SIRT/sorafenib subgroups. Similar nonsignificant results occurred in alcohol-, viral-, and NASH/NAFLD-induced HCC subgroups. Conclusion Baseline CT-derived BMD does not predict OS in advanced HCC patients, indicating it is not a robust prognostic biomarker in this setting. Low BMD does not affect a patient’s resilience to SIRT.

  • Open Access

    An International Phase 4 Study of Lenvatinib and Sorafenib in Real-World Patients with Unresectable Hepatocellular Carcinoma: Final Analysis

    by Markus Peck-Radosavljevic, Akhmed Abdelgafur, Alessandro Granito, Antonio Gasbarrini, Yuk Ting Ma, Edward Mena, José Luis Lledó-Navarro, José Presa, Arndt Weinmann, Miriam T. Levy, et al.

    Introduction: The phase 3 REFLECT trial demonstrated the efficacy and safety of lenvatinib versus sorafenib in the first-line treatment of patients with unresectable hepatocellular carcinoma (uHCC). We report results from STELLAR, a non-interventional post-marketing study. The primary objectives were to characterize hepatotoxicity and overall safety of lenvatinib in patients from Western regions with uHCC. Methods: STELLAR was a prospective, open-label, observational, phase 4 study of patients treated with lenvatinib (n = 193). A cohort of sorafenib-treated patients (n = 123) was included as an internal reference group. The treating physician made the decision to treat patients with lenvatinib or sorafenib before enrollment. Study drugs were administered according to the Summary of Product Characteristics guidelines. Safety and efficacy evaluations were performed according to standard clinical practice at each site. The primary endpoint was safety. Secondary endpoints included treatment exposure and overall survival. Results: The median duration of treatment with lenvatinib or sorafenib was 6.5 months (range, 0.2–33.1 months) and 4.4 months (range, 0.5–30.7 months), respectively. Hepatotoxicity treatment-emergent adverse events (TEAEs) were observed in 26.9% of lenvatinib-treated patients and 33.3% of sorafenib-treated patients. The most frequently reported hepatotoxicity TEAEs were hepatic encephalopathy (7.8%; lenvatinib cohort) and ascites (11.4%; sorafenib cohort), respectively. Overall, 85.0% of lenvatinib-treated patients and 84.6% of sorafenib-treated patients experienced ≥1 TEAE. Median overall survival (95% CI) was 16.9 months (14.1–not estimable) in lenvatinib-treated patients. Conclusion: Our findings support the established safety and efficacy of lenvatinib in first-line patients with uHCC.


  • Open Access

    STRmie-HD enables interruption-aware HTT repeat genotyping and somatic mosaicism profiling across sequencing platforms

    by Alessandro Napoli, Niccolò Liorni, Tommaso Biagini, Agnese Giovannetti, Alessia Squitieri, Luca Miele, Andrea Urbani, Viviana Caputo, Antonio Gasbarrini, Ferdinando Squitieri, et al.

    Short tandem repeat expansions in exon 1 of the HTT gene drive Huntington’s disease (HD) pathogenesis, with disease onset and progression heavily influenced by somatic mosaicism and sequence interruptions. While sequencing technologies enable repeat sizing, many computational tools lack the resolution to capture subtle interruption motifs and allele-specific somatic variation. We present STRmie-HD, an alignment-free, de novo framework for interruption-aware genotyping and quantitative profiling of somatic mosaicism at single-read resolution. The tool parses individual reads to quantify uninterrupted CAG tract length, CCG repeat content, and critical interruption variants, including Loss of Interruption (LOI) and Duplication of Interruption (DOI). Validated across Illumina, PacBio SMRT, and Oxford Nanopore platforms, STRmie-HD demonstrates high concordance with reference genotypes and superior sensitivity in identifying rare interruption patterns that conventional tools often overlook. Furthermore, it implements somatic mosaicism metrics to characterize repeat dynamics, successfully distinguishing the higher somatic expansion burden in brain tissues compared to peripheral blood. STRmie-HD offers a comprehensive and extensible solution for high-resolution molecular characterization of HTT variation, providing a robust framework for patient stratification and genetic research in HD. Graphical Graphical STRmie-HD flowchart. STRmie-HD is a comprehensive analytical framework that processes sequencing reads to analyze CAG/CCG trinucleotide repeats, interruption variants, and somatic mosaicism in the HTT gene. The workflow begins with sequencing reads (FASTA/FASTQ) that can undergo optional custom processing eq]based on the sequencing design. These reads are then fed into a regular expression-based engine (STRmie-HD) to identify CAG and CCG motifs. The identified motifs lead to the estimation of CAG/CCG alleles, visualized as distinct peaks representing different allele sizes, interruption variant assessment, and somatic mosaicism quantification. STRmie-HD produces an HTML output that wraps this information into a report.

  • Open Access

    Bowel urgency in inflammatory bowel disease: A concept analysis

    by Daniele Napolitano, Mattia Bozzetti, Valentina Vanzi, Alessio Lo Cascio, Ivan Capobianco, Antonio Gasbarrini, Loris Riccardo Lopetuso, Franco Scaldaferri

    Background: Bowel urgency is a distressing and often underrecognized symptom of inflammatory bowel disease (IBD). It represents a sudden and compelling need to defecate that is difficult to defer and strongly affects patients’ quality of life. Despite its clinical importance, the concept of bowel urgency remains poorly characterized and inconsistently measured across studies. Aims: This review aims to clarify the conceptual boundaries of bowel urgency, summarize recent clinical and mechanistic evidence, and provide a framework to guide its assessment and management in clinical practice and research. Methods: A narrative concept analysis was conducted using Walker and Avant’s 8-step method. Evidence from clinical, physiological, and patient-reported outcome studies published between 2016 and 2025 was integrated across major databases (MEDLINE, PsycInfo, Scopus, Web of Science) to identify defining attributes, antecedents, and consequences of bowel urgency in IBD. Results: Seven defining attributes were identified: sudden onset, perceived uncontrollability, compressed time to toilet, fear or risk of incontinence, anticipatory anxiety, behavioral planning or avoidance, and persistence despite inflammatory quiescence. Biological antecedents include rectal inflammation, hypersensitivity, and altered pelvic floor function, while psychosocial factors such as vigilance and anxiety contribute to chronicity. Consequences extend from emotional distress and reduced social participation to increased healthcare utilization. Current tools, including the Urgency Numeric Rating Scale, capture intensity but fail to reflect multidimensional impact. Conclusions: Bowel urgency is a multidimensional clinical construct with physiological, psychological, and behavioral components. Its systematic assessment should become a routine element of IBD care and a standardized endpoint in clinical trials. Developing and validating a multidimensional, IBD-specific urgency measure would bridge symptom monitoring and patient-centered outcomes.